CytomX Therapeutics, Inc.
CTMXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company carries a $808.4M market cap, placing it firmly in the small-cap category. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
Market Cap
$808.4M
Beta
2.14
P/E (TTM)
—
P/E (Fwd)
-7.84
EPS (TTM)
$-0.57
EPS (Fwd)
$-0.47
ROE
-37.8%
ROA
-19.6%
Cash
$330.3M
Total Debt
$5.7M
Free CF
-$75.2M
52W Change
77.5%
Annual Financials
Cash vs Debt
Where CTMX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CTMX finished 9.27% below its 150-day moving average ($4.10) and 10.58% below its 200-day moving average ($4.16). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CTMX overbought or oversold?
At the September 3, 2026 close, CTMX's RSI(14) was 61.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $330.3M in cash and $5.7M in debt, CTMX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$75.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -37.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $53.2M (2022) to $76.2M (2025), reflecting a 43% increase over the period.
A beta of 2.14 means CTMX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, CTMX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CTMX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.